|
WO2015038680A1
|
|
Drug conjugates of gga and gga derivatives
|
|
US2015133431A1
|
|
Gga derivatives
|
|
WO2014151703A1
|
|
Ocular formulations
|
|
WO2014151697A1
|
|
Therapeutic uses for geranylgeranyl acetone and derivatives thereof
|
|
WO2014151719A1
|
|
Sublingual formulations including geranylgeranylacetone and geranylgeranylacetone derivatives
|
|
WO2014107686A1
|
|
Methods for treating neuron damage
|
|
US9119808B1
|
|
Treating neurodegenerative diseases with GGA or a derivative thereof
|
|
WO2014055440A1
|
|
Preparation of gga and derivatives thereof and their co-crystallization with urea or thiourea
|
|
WO2014163643A1
|
|
Gga and gga derivatives compositions thereof and methods for treating neurodegenerative diseases including paralysis including them
|
|
US2014275282A1
|
|
Treating osteopenia and related disorders with geranylgeranyl acetone and derivatives thereof
|
|
US2014274967A1
|
|
Polyisoprenyl derivatives and uses thereof
|
|
US2014187646A1
|
|
Geranylgeranylacetone formulations and retinal and systemic delivery thereof
|
|
US2014275091A1
|
|
Ocular formulations comprising geranylgeranylacetone derivatives for intraocular delivery
|
|
US2014275280A1
|
|
Therapeutic uses of geranylgeranyl acetone and derivatives thereof
|
|
US2014275281A1
|
|
Geranylgeranyl acetone and derivatives thereof for intranasal administration
|
|
US2014275631A1
|
|
Process for synthesizing GGA and its derivatives
|
|
US2015025077A1
|
|
Gga and gga derivatives compositions thereof and methods for treating neurodegenerative diseases including paralysis including them
|
|
WO2013130242A1
|
|
Geranylgeranylacetone formulations
|
|
EP2763949A1
|
|
Geranylgeranylacetone derivatives
|
|
AU2011295920A1
|
|
Methods for treating neurodegenerative diseases
|
